Registered title, quoted from ClinicalTrials.gov
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06555068, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Aged < 60, natural menopause (defined as spontaneous cessation of regular menses for at least 12 consecutive months in the absence of other pathological or physiological causes) with E2 and FSH at postmenopausal levels; or
Inclusion criterion 7
Previous use of fulvestrant for cohort of HRS-6209 in combination with fulvestrant (efficacy expansion stage).
Exclusion criterion 5
Surgical treatment (except for needle biopsy or PICC catheterization or PORT catheterization), chemotherapy (except for 5-Fu drugs), immunotherapy, macromolecular targeted therapy, etc. within 4 weeks before the first dose; Received endocrine therapy, 5-FU chemotherapy or radiotherapy within 2 weeks before the first dose; Small molecule targeted drugs need to be washed out for 2 weeks or 5 half-lives (whichever is longer);
Exclusion criterion 16
ECOG performance status (PS) score of 0-1;
Inclusion criterion 2
With at least one extracranial measurable target lesion at baseline per RECIST v1.1;
Inclusion criterion 10
With active autoimmune diseases, history of immunodeficiency and history of autoimmune diseases, history of diseases or syndromes that require systemic corticosteroids or immunosuppressive drugs, other acquired (HIV infection) or congenital immunodeficiency, or history of organ transplantation (including allogeneic bone marrow transplantation);
Exclusion criterion 10
Had other concurrent malignant tumors in the past 5 years, except: 1. Cervical carcinoma in situ that has been cured, 2. Second primary cancer that has been cured without recurrence within five years;
Exclusion criterion 13
Pregnant or lactating women, or females planning to become pregnant during the study period;
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06555068, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Females aged 18-75 years (inclusive);
- ECOG performance status (PS) score of 0-1;
- Patients with histopathologically confirmed metastatic or unresectable locally advanced breast cancer;
- Patients with advanced malignant solid tumors confirmed by histopathology or cytopathology, who have failed standard treatment, or for whom no effective standard treatment regimen is available, or who are unable to receive further standard treatment.
- Menopausal status:
- Having had bilateral oophorectomy, or aged ≥ 60 years old; or
- Aged < 60, natural menopause (defined as spontaneous cessation of regular menses for at least 12 consecutive months in the absence of other pathological or physiological causes) with E2 and FSH at postmenopausal levels; or
- Premenopausal or perimenopausal patients, agree to start or continue receive LHRH agonists during the study (exclude from the QT/QTc group).
- Disease progression evidenced by imaging during or after the last systemic anti-tumor treatment prior to the first dose (limited to the efficacy expansion stage);
- With at least one extracranial measurable target lesion at baseline per RECIST v1.1;
- Life expectancy of > 3 months;
- Adequate organ and marrow function as defined by the protocol;Female subjects of childbearing potential should agree to adopt effective contraceptive measures during the study period and within 7months after the end of the study treatment; female subjects of childbearing potential must have a negative serum HCG test result within 7 days before enrollment in the study and must not be in the lactation;
- Voluntarily participate in this clinical study, be willing and able to comply with procedures related to clinical visits and study, and understand and have signed written informed consent.
Exclusion Criteria:
- With symptomatic visceral metastases deemed unfit for endocrine therapy by the investigator;
- With active brain metastases, carcinomatous meningitis, spinal cord compression, or a history of primary tumors of the central nervous system;
- History of clinically significant cardiovascular disease, including;
- Abnormal ECG findings, which are judged by the investigator to be clinically significant and and need to intervene;
- Previous use of fulvestrant for cohort of HRS-6209 in combination with fulvestrant (efficacy expansion stage).
- With factors that affect oral medication, active gastrointestinal diseases, or other diseases that may obviously affect drug absorption, distribution, metabolism, or excretion;
- With clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding;
- Active infection or unexplained fever > 38.5 °C during the screening period or on the day of first dose;
- With uncontrollable chronic systemic complications as judged by the investigator.
- With active autoimmune diseases, history of immunodeficiency and history of autoimmune diseases, history of diseases or syndromes that require systemic corticosteroids or immunosuppressive drugs, other acquired (HIV infection) or congenital immunodeficiency, or history of organ transplantation (including allogeneic bone marrow transplantation);
- With acute infection or active tuberculosis requiring medication.
- With a known history of clinically significant liver disease, untreated active hepatitis;
- Had other concurrent malignant tumors in the past 5 years, except: 1. Cervical carcinoma in situ that has been cured, 2. Second primary cancer that has been cured without recurrence within five years;
- Use of moderate and strong CYP3A4 inhibitors within 1 week or moderate and strong CYP3A4 inducers within 2 weeks prior to the first dose;
- Use of any drugs with the risk of prolonging QT/QTc interval or causing torsade de pointes (TdP) within 4 weeks prior to the first dose, and with previous congenital QT interval prolongation syndrome or a family history of QT interval prolongation, implanted pacemakers or automatic implantable cardioverter defibrillators, uncorrectable electrolyte disorders, and other factors that may affect the QT/QTc study;
- Surgical treatment (except for needle biopsy or PICC catheterization or PORT catheterization), chemotherapy (except for 5-Fu drugs), immunotherapy, macromolecular targeted therapy, etc. within 4 weeks before the first dose; Received endocrine therapy, 5-FU chemotherapy or radiotherapy within 2 weeks before the first dose; Small molecule targeted drugs need to be washed out for 2 weeks or 5 half-lives (whichever is longer);
- Pregnant or lactating women, or females planning to become pregnant during the study period;
- With clear history of neural or mental disorders or with history of psychotropic abuse or drug abuse;
- Subjects who are expected to receive other anti-tumor therapies or drugs during this study.
Quoted from ClinicalTrials.gov, NCT06555068, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06555068, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.